2017 PTAB - A Year in Review
2017 was a year for the record books at the Patent Trials and Appeal Board (PTAB), which has included newly created standard operating procedures from the PTAB, a landmark en banc ruling from the Court of Appeals for the Federal Circuit, and a series of informative decisions from PTAB impacting multiple proceedings against the same patent.
Please join Foley attorneys, George Beck, Andrew Cheslock, and Steve Maebius, as they discuss the year’s major developments and how they may impact practice before the PTAB going forward.
Specific topics will include:
2017 Trends and Statistics
SCOTUS on IPRs – including SAS Institute Inc. v. Joseph Matal and Oil States Energy Services LLC v. Greene’s Energy Group, LLC
PTAB Amendment Process – via Aqua Products v. Matal
Trends in Pharmaceutical IPRs Filed by Generic Petitioners
PTAB Grants Rare Request for Additional Discovery in Mylan v. Allergan IPR
- Next Up: Section 301 Companies and Global Markets Should Prepare for the Risk of Rising U.S.-China Trade Tensions
- USPTO Withdraws Newly Characterized Antigen Test For Written Description Of Antibodies
- Exergen Corp. v. Kaz USA Represents Another In A Recent String Of Recent Setbacks For Patent Infringement Defendants On Eligibility Challenges